Adia Nutrition (ADIA) Operating Leases (2024 - 2026)
Adia Nutrition's (ADIA) quarterly Operating Leases came in at $82010.0 in Q2 2026, down 14.64% quarter-over-quarter from $96076.0 in Q1 2026.
Analysis
Adia Nutrition (ADIA) Operating Leases (2024 - 2026) Analysis & Trends
Adia Nutrition (ADIA) has reported Operating Leases for 3 consecutive years, with $82010.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Operating Leases changed N/A year-over-year to $82010.0 in Q2 2026; TTM through Jun 2026 was $82010.0, a N/A change from a year earlier, with the FY2025 full-year figure at $109868.0, down 29.4% from the prior year.
- Operating Leases was $82010.0 for Q2 2026 at Adia Nutrition, down from $96076.0 in the prior quarter.
- Over five years, Operating Leases peaked at $155624.0 in Q4 2024 and troughed at $82010.0 in Q2 2026.
- A 3-year average of $110894.5 and a median of $102972.0 in 2025 frame the typical range for Operating Leases.
- The widest YoY moves for Operating Leases: up 29.4% in 2025, down 29.4% in 2025.
- Over 3 years, Operating Leases stood at $155624.0 in 2024, then declined by 29.4% to $109868.0 in 2025, then retreated by 25.36% to $82010.0 in 2026.
- The last three Operating Leases figures came in at $82010.0 (Q2 2026), $96076.0 (Q1 2026), and $109868.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 9.96 Bn | 9.12 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.47 Bn | 5.47 Bn | - |
| 3 | Iovance Biotherapeutics | 4.64 Bn | 4.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.25 Bn | 2.28 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Precigen | 2.79 Bn | 2.79 Bn | 52.17 Mn |
| 7 | Beam Therapeutics | 2.58 Bn | 2.58 Bn | - |
| 8 | Sarepta Therapeutics | 2.12 Bn | 1.33 Bn | 251.87 Mn |
| 9 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
| 10 | Adia Nutrition | 11.33 Mn | 11.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 82,010.00 |
| Mar 31, 2026 | 96,076.00 |
| Dec 31, 2025 | 109,868.00 |
| Dec 31, 2024 | 155,624.00 |